Learn More
BACKGROUND We have raised a panel of broad spectrum neutralizing monoclonal antibodies against the highly pathogenic H5N1 avian influenza virus, which neutralize the infectivity of, and afford protection against infection by, most of the major genetic groups of the virus evolved since 1997. Peptide mimics reactive with one of these broad spectrum H5N1(More)
The presence of neutralizing epitopes in human papillomavirus (HPV) L1 virus-like particles (VLPs) is the structural basis of prophylactic vaccines. An anti-HPV16 neutralizing monoclonal antibody (N-mAb) 26D1 was isolated from a memory B cell of a human vaccinee. The pre-binding of heparan sulfate to VLPs inhibited the binding of both N-mAbs to the antigen,(More)
After 14-years of development, the first prophylactic vaccine against the Hepatitis E virus (HEV) has been marketed since 2012 (Wu et al., 2012). However, the neutralizing epitopes of HEV are not completely defined. E2s, a protruding homodi-mer domain of HEV capsid protein, is responsible for interacting with host cells to initiate infection (Li et al.,(More)
  • 1